|
Translational Research on Cancer Metabolism: Multidisciplinary Approaches for Diagnosis and Treatment
The anticipated outcome of the call is the development of innovative, personalised approaches for cancer diagnosis, patient stratification, and treatment, grounded in a deeper mechanistic understanding of metabolic alterations in cancer.
Aim 1: Enabling better cancer diagnostics and monitoring through metabolic biomarkers
Novel metabolic biomarkers and technologies offer major opportunities for earlier cancer detection, improved patient stratification and more accurate monitoring of treatment response and disease progression.
Aim 2: Intercepting metabolic vulnerabilities to improve precision medicine
Metabolic reprogramming in cancer creates unique dependencies that can be exploited therapeutically. Tumours often develop distinct metabolic signatures, shaped by oncogenic mutations, which drive tumour initiation, progression, therapy resistance, and metastasis. These metabolic adaptations open the door to precision medicine approaches that target defined metabolic vulnerabilities with tailored interventions.
General requirements:
- Applications incorporating spatial transcriptomic, single-cell/multi-omic approaches are strongly encouraged,
- as are other innovative methodologies such as artificial intelligence, liquid biopsy, radiomics, and advanced computational approaches.
- Proposals may also include strong biomedical components, for example organoids, cancer vaccines, nanoparticles, or other advanced model systems.
- Interdisciplinary approaches integrating expertise from engineering, informatics, physics, or related fields alongside biology and medicine, are particularly welcome (provided they clearly address unmet clinical needs and demonstrate potential impact on patients and populations).
- Applicants are encouraged to consult / communicate with patients and / or their representatives during preparation of the proposal and during their research projects.
The following types of projects are excluded from this call:
- Studies based exclusively on preclinical models limited to established cell lines;
- Phase III and IV clinical trials;
- Studies not compliant with applicable European Union regulations on State aid and services of general economic interest, in particular Commission Regulation (EC) No 800/2008 and Commission Regulation (EU) No 651/2014, as well as related communications and guidance documents.
Important facts:
- 21.07.2026 – pre-proposals
- 13.01.2027 – full-proposals
- Joint projects with 3 to 6 partners (max 2 partners from one country)
- One early-career researcher mandatory
- One pre-clinical research team and one clinical research team mandatory in consortium
Participating countries:
Austria, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Malta, Poland, Romania, Slovakia, Spain, Taiwan, Turkiye
Important LINKs:
https://transcan.eu/funding/calls/joint-call-jtc-2026-.kl
|
